The Prodrug Approach: A Successful Tool for Improving Drug Solubility

被引:202
作者
Jornada, Daniela Hartmann [1 ]
dos Santos Fernandes, Guilherme Felipe [1 ]
Chiba, Diego Eidy [1 ]
Ferreira de Melo, Thais Regina [1 ]
dos Santos, Jean Leandro [1 ]
Chung, Man Chin [1 ]
机构
[1] Univ Estadual Paulista, UNESP, Fac Ciencias Farmaceut, Rodovia Araraquara Jau Km 01, BR-14801902 Araraquara, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
prodrug; solubility; water-soluble prodrugs; solubility of prodrugs; molecular modification; WATER-SOLUBLE PRODRUGS; ADENOSINE RECEPTOR ANTAGONISTS; HISTONE DEACETYLASE INHIBITORS; IN-VIVO EVALUATION; PALM OIL; ANTISTAPHYLOCOCCAL EFFICACY; ESLICARBAZEPINE ACETATE; BIOLOGICAL-ACTIVITY; GAMMA-TOCOTRIENOL; TOPOISOMERASE-IV;
D O I
10.3390/molecules21010042
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prodrug design is a widely known molecular modification strategy that aims to optimize the physicochemical and pharmacological properties of drugs to improve their solubility and pharmacokinetic features and decrease their toxicity. A lack of solubility is one of the main obstacles to drug development. This review aims to describe recent advances in the improvement of solubility via the prodrug approach. The main chemical carriers and examples of successful strategies will be discussed, highlighting the advances of this field in the last ten years.
引用
收藏
页数:31
相关论文
共 126 条
[1]  
Abu-Jaish A., 2014, PRODRUGS DESIGN, P77
[2]  
Adams J D, 1993, J Natl Cancer Inst Monogr, P141
[3]   Preparation and in vivo evaluation of a water-soluble prodrug for 2R-γ-tocotrienol and as a two-step prodrug for 2,7,8-trimethyl-2S-(β-carboxyethyl)-6-hydroxychroman (S-γ-CEHC) in rat [J].
Akaho, Nami ;
Takata, Jiro ;
Fukushima, Takeshi ;
Matsunaga, Kazuhisa ;
Hattori, Akihiro ;
Hidaka, Ryoji ;
Fukui, Kosuke ;
Yoshida, Miyako ;
Fujioka, Toshihiro ;
Karube, Yoshiharu ;
Imai, Kazuhiro .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (09) :1502-1510
[4]   Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[5]   The role of glutathione in cancer [J].
Balendiran, GK ;
Dabur, R ;
Fraser, D .
CELL BIOCHEMISTRY AND FUNCTION, 2004, 22 (06) :343-352
[6]   Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist [J].
Beaumont, K ;
Webster, R ;
Gardner, I ;
Dack, K .
CURRENT DRUG METABOLISM, 2003, 4 (06) :461-485
[7]   ESLICARBAZEPINE ACETATE: A WELL-KEPT SECRET? [J].
Ben-Menachem, Elinor .
EPILEPSY CURRENTS, 2010, 10 (01) :7-8
[8]   EB1627:: a soluble prodrug of the potent anticancer cyanoguanidine CHS828 [J].
Binderup, E ;
Björkling, F ;
Hjarnaa, PV ;
Latini, S ;
Baltzer, B ;
Carlsen, M ;
Binderup, L .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (10) :2491-2494
[9]  
Boules Ramy, 2012, P T, V37, P395
[10]   Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections [J].
Brade K.D. ;
Rybak J.M. ;
Rybak M.J. .
Infectious Diseases and Therapy, 2016, 5 (1) :1-15